On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during ...

Allan Shaw, Chief Financial Officer and Chief Business Officer at Create Medicines, is back on the Business of Biotech this week, with a temperature check on biotech funding and the IPO market.

The simultaneous impacts of global trade shifts, U.S. tax reforms, and changing drug pricing policies have prompted life ...

On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into ...

Biotech always has been a challenging realm. The science is innovative, its technology makes it capital-intensive, and the related risks are unpredictable. When funding, if partnerships and ...

What comes after what comes next in pharmaceutical packaging, storage and distribution? The pharmaceutical industry is entering a new era, driven by the rise of biologic therapies — monoclonal ...

Patients rarely decline clinical studies out of unwillingness — they say “no” because clinical trials are often complex, unclear, and fail to feel personally meaningful. Every decision to participate ...

While most agree that patient experience is essential, few can demonstrate its tangible impact. In today’s clinical trial environment — where equity, access, and retention are under growing scrutiny — ...

Growing up on a commune, you learn from an early age that your primary function is to serve the community. Filling gaps isn’t optional — it’s expected. I become skilled at quickly diagnosing what is ...

On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to ...

At Samsung Biologics, we understand that the path from DNA to vial is anything but simple — especially when it comes to the development and manufacture of complex biologics. These intricate molecules ...

Crown Bioscience, a global contract research organization (CRO), is expanding its U.S. footprint with a new site in Kannapolis, North Carolina. The facility will focus on preclinical oncology services ...